Elanco Animal Health Inc (ELAN) stock
ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30129% above fair value
$25.85−0.56 (-2.12%)
Close on Nov 17, 2026Market cap $12.92BP/E –Yield –
Elanco Animal Health total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Elanco Animal Health's total debt was $3.92B at Jun 30, 2026. For fiscal 2025 it was $4.02B, down 7.0% from the year before. The highest annual figure on record is $6.32B in fiscal 2021.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.02B | -7.0% |
| FY2024 | Dec 31, 2024 | $4.32B | -25.2% |
| FY2023 | Dec 31, 2023 | $5.77B | -1.1% |
| FY2022 | Dec 31, 2022 | $5.84B | -7.6% |
| FY2021 | Dec 31, 2021 | $6.32B | +3.1% |
| FY2020 | Dec 31, 2020 | $6.13B | +160.2% |
| FY2019 | Dec 31, 2019 | $2.36B | -4.7% |
| FY2018 | Dec 31, 2018 | $2.47B | – |
| FY2017 | Dec 31, 2017 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.92B | -6.9% |
| Q1 FY2026 | Mar 31, 2026 | $3.99B | -9.2% |
| Q4 FY2025 | Dec 31, 2025 | $4.02B | -7.0% |
| Q3 FY2025 | Sep 30, 2025 | $4.02B | -7.6% |
| Q2 FY2025 | Jun 30, 2025 | $4.21B | -25.8% |
| Q1 FY2025 | Mar 31, 2025 | $4.40B | -23.8% |
| Q4 FY2024 | Dec 31, 2024 | $4.32B | -25.2% |
| Q3 FY2024 | Sep 30, 2024 | $4.36B | -26.3% |
| Q2 FY2024 | Jun 30, 2024 | $5.68B | -6.4% |
| Q1 FY2024 | Mar 31, 2024 | $5.77B | -4.2% |
| Q4 FY2023 | Dec 31, 2023 | $5.77B | -1.1% |
| Q3 FY2023 | Sep 30, 2023 | $5.91B | +0.1% |
| Q2 FY2023 | Jun 30, 2023 | $6.06B | -0.0% |
| Q1 FY2023 | Mar 31, 2023 | $6.02B | -1.9% |
| Q4 FY2022 | Dec 31, 2022 | $5.84B | -7.6% |
| Q3 FY2022 | Sep 30, 2022 | $5.90B | -6.8% |
| Q2 FY2022 | Jun 30, 2022 | $6.06B | -0.6% |
| Q1 FY2022 | Mar 31, 2022 | $6.13B | -0.4% |
| Q4 FY2021 | Dec 31, 2021 | $6.32B | +3.1% |
| Q3 FY2021 | Sep 30, 2021 | $6.33B | +3.2% |
| Q2 FY2021 | Jun 30, 2021 | $6.10B | +196.5% |
| Q1 FY2021 | Mar 31, 2021 | $6.16B | +198.8% |
| Q4 FY2020 | Dec 31, 2020 | $6.13B | +160.2% |
| Q3 FY2020 | Sep 30, 2020 | $6.14B | +160.2% |
| Q2 FY2020 | Jun 30, 2020 | $2.06B | -14.6% |
| Q1 FY2020 | Mar 31, 2020 | $2.06B | -16.4% |
| Q4 FY2019 | Dec 31, 2019 | $2.36B | -4.7% |
| Q3 FY2019 | Sep 30, 2019 | $2.36B | -4.8% |
| Q2 FY2019 | Jun 30, 2019 | $2.41B | – |
| Q1 FY2019 | Mar 31, 2019 | $2.47B | – |
| Q4 FY2018 | Dec 31, 2018 | $2.47B | – |
| Q3 FY2018 | Sep 30, 2018 | $2.48B | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
See a number that looks wrong?